Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: twentyfirstcenturyfox who wrote (11921)	1/22/2003 9:04:39 PM
From: DaveAu	Read Replies (1) \| Respond to of 14101

Hi Fox, Did you get those numbers for the SAP program from the HC site ? Dave

To: twentyfirstcenturyfox who wrote (11921)	1/25/2003 1:05:52 PM
From: Mark Bartlett	Read Replies (1) \| Respond to of 14101

21st, <<This is an open-label study, being conducted in Canada, with the express approval of HC. The purpose of the study is to allow patients to be treated with WF10 through Health Canada's controlled Special Access Programme (SAP). Dimethaid is conducting the program. Health Canada has approved this study as a compassionate use protocol. As of May 22, 2001, 36 patients (22 males and 14 females) have been enrolled. The study is ongoing.>> I was certainly aware that there was access via the SAP, but not specifically the open label study. However, when one thinks about it, it stands to reason that if HC is going to allow the use of the drug, it seems reasonable that one would collect data from that use -- if for no other reason than to ensure it is not having any serious, unanticipated side-effects. I am wondering if this may even be a prerequisite to get SAP approval by HC. MB